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Abstract
Background: Complete metastasectomy provides a real chance for long-term survival in patients with
oligometastatic colorectal cancer (CRC). For inoperable patients, we evaluated in this study intensity-modulated and
image-guided radiotherapy (IMRT-IGRT) by helical tomotherapy.
Methods: Twenty-four CRC patients with ≤ 5 metastases were enrolled, receiving a dose of 50 Gy in fractions of
5 Gy. No limitations concerning dimension or localization of the metastases were imposed. Whole body PET-CT
was performed at baseline and 3 months after the initiation of RT to evaluate the metabolic response rate
according to PET Response Criteria in Solid Tumors (PERCIST) version 1.0.
Results: A total of 53 metastases were treated. Seventeen patients (71%) received previously ≥ 1 line of
chemotherapy for metastatic disease, displaying residual (n = 7) or progressive (n = 10) metabolic active
oligometastatic disease at time of inclusion. Most common sites were the lung, liver and lymphnodes. One patient
(4%) experienced grade 3 dysphagia. Twenty-two patients were evaluated by post-treatment PET-CT. Twelve
patients achieved a complete (n = 6) or partial (n = 6) metabolic response, resulting in an overall metabolic
response rate of 55%. At a median follow-up of 10 months, 7 patients (29%) are in remission, of which 5 received
previous chemotherapy with residual oligometastatic disease at time of inclusion. The actuarial 1-year local control,
progression-free survival, and overall survival were 54%, 14% and 78%.
Conclusions: Helical tomotherapy delivering 10 fractions of 5 Gy resulted in a metabolic response rate of 55%, and
appeared to be attractive as consolidation of inoperable oligometastatic disease after effective chemotherapy.
Trial registration: Eudract 2008-008300-40; NCT00807313
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Background
Nearly one fourth of the patients with newly diagnosed
colorectal cancer (CRC) present synchronous liver metas-
tases and more than half of the resected CRC patients
develop distant recurrence during follow-up [1]. The
diagnosis of metastatic CRC (mCRC) does however not
equal an acute fatal illness and might be classified more
as a chronic disease in patients with a clinical disease
state between locoregionally confined and widely spread
metastatic disease, so called oligometastatic disease [2,3].
It is well understood today that a complete metastasect-
omy provides a real chance for long-term survival in
those patients, with documented 10-year overall survival
(OS) rates in 1 out of 6 mCRC patients which underwent
hepatic resection [4]. According to the data of the rando-
mized EORTC intergroup Trial 40983, the perioperative
administration of 5-fluorouracil (5-FU) and oxaliplatin
(FOLFOX) has emerged as a new standard of care in
mCRC patients with limited resectable liver metastases,
by increasing the 3-year progression-free survival (PFS)
with 8% (36% versus 28% without perioperative che-
motherapy) [5]. Despite the improvements in surgical
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limitations imposed by localization, multifocal character,
size, or comorbidities still exclude the major part of
mCRC patients from undergoing metastasectomy [6].
Aiming at ablating metastases while preserving the sur-
rounding healthy tissues, there has been an expansion
over the past decade in the use of non-surgical local abla-
tive alternatives such as radiofrequency ablation (RFA)
and stereotactic body radiotherapy (SBRT), the latter a
tailored delivery of tumoricidal doses of radiation in a
minimal number of fractions to small lesions by the com-
bination of high conformal RT and rigorous localization
of the target by image-guided RT (IGRT) [7-10]. In the
eradication of liver- and lungmetastases by SBRT, limited
toxicity rates and sustain e dl o c a lc o n t r o l( L C )a r e
reported by several authors up [7,8]. However, in order
to allow delivery of those cytotoxic doses, SBRT requires
carefully selection of the metastases on the base of their
localization and dimension. Our institution previously
explored in a pilot study the efficacy and toxicity of heli-
cal tomotherapy, a technology combining rotational
intensity-modulated RT (IMRT) and IGRT by megavol-
tage (MV) computed tomography (CT) scanning, in
patients with oligometastatic CRC who were not amen-
able for metastasectomy and (further) systemic therapy
[9]. In order to suit a variety of treatment sites including
large metastases and critically located lesions, we used a
moderately hypofractionated regimen, delivering 10 frac-
tions of 4 Gy. This schedule resulted in a complete meta-
bolic response (CMR), the primary objective, in 5 out of
23 enrolled oligometastatic CRC patients [9]. Besides,
helical tomotherapy displayed a very safe toxicity profile,
with grade 2 and 3 toxicity recorded in only 9% and 4%
of the patients, respectively [9]. Taking into account the
rather disappointing 1-year LC rate of 54% in this pilot
study, we now aimed for higher response and LC rates in
those patients. To do so, we investigated in this study the
efficacy and toxicity of helical tomotherapy delivering
50 Gy in daily fractions of 5 Gy in patients with inoper-
able oligometastatic CRC. The primary objective was to
evaluate the CMR rate 3 months after initiation of RT by
performing whole-body
18 F-fluorodeoxyglucose (FDG)-
positron emission tomography (PET) at baseline and at
evaluation. Secondary endpoints were toxicity, LC and
PFS.
Methods
Patient population
Patients with a radically resected primary tumor with the
histological proof of a colorectal adenocarcinoma and at
time of inclusion 1 to 5 metastases, showing increased
metabolism on
18FDG-PET, were eligible for this study.
No limitations were imposed on the localization or
dimension of the metastases. Patients were required to
have an Eastern Cooperative Oncology Group perfor-
mance status of ≤ 2, to be > 18 years old and inoperable
by the localization, number or dimension of the metas-
tases, medically unfit to undergo resection or refusing
surgery. Patients were not permitted to receive che-
motherapy within 1 month before initiation of RT.
Patients who did not receive previous chemotherapy for
metastatic disease had to be medically unfit to undergo
systemic treatment or refusing chemotherapy. Patients
with Child B or C liver cirrhosis or a functional liver
volume < 1000 cc in case of liver metastases and a lung
diffusion capacity for carbon monoxide (DLCO) of < 30%
in case of lung metastases were excluded. Patients with
an active second primary tumor were excluded. All
patients signed study-specific informed consent. The pro-
tocol was reviewed and approved by the Ethical Commit-
tee and registered (inter)nationally (Eudract 2008-
008300-40; NCT00807313).
Pre-treatment evaluation and radiotherapy technique
Pre-treatment evaluation included a complete medical
history, physical examination, a pre-treatment free
breathing
18FDG-PET and computed tomography (CT)
using a dedicated PET-CT camera (Gemini TF, Philips
Medical Systems, OH, USA) and laboratory tests includ-
ing carcinoembryonic antigen (CEA) with assessment of
the Child-Pugh parameters and liver enzymes in patients
with liver metastases. RT was performed using the
TomoTherapy Hi⋅A r tI IS y s t e m( T o m o T h e r a p yI n c . ,
Madison, WI), which fully integrates IGRT by means of
MVCT scanning and IMRT by means of dynamic rota-
tional therapy [10]. The gross tumor volume (GTV)
included the visible gross tumor mass on CT. The GTV
was expanded by a 10, 10 and 12 mm for the anteropos-
terior, laterolateral and craniocaudal direction, respec-
tively, to create the planning target volume (PTV), fully
encompassing the
18FDG-PET-positive volume. The
planning goals were to deliver at least 95% of the pre-
scribed dose to at least 95% of the PTVs, while keeping
the maximum dose (Dmax) to the PTV below 105%. The
volume of lung receiving more than 20 Gy (V20) was kept
below 20% in case of lung irradiation. In patients with
liver metastases, the liver volume receiving more than 22
Gy (V22)a n d3 0G y( V 30) was kept to less than 50% and
30%, respectively. A Dmax of 36 Gy (72% of the prescribed
dose) was set to the spinal cord. In case of intersection
b e t w e e nt h eP T Va n dh o l l o wv i s c o u so r g a n s( s m a l l
bowel, large bowel, stomach or oesophagus) of ≥ 5c c ,a
PTV subvolume was defined at this interface with a Dmax
of 40 Gy (80% of the prescribed dose) to this overlap
volume. The treatment was delivered daily in 10 frac-
tions, excluding weekends. Before each treatment session,
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CT scan modality and were repositioned after co-regis-
tration of these images with the planning kilovoltage
(kV)-CT scan.
Toxicity monitoring
Toxicity was evaluated and scored according to the
National Cancer Institute Common Terminology Cri-
t e r i af o rA d v e r s eE v e n t s( N C IC T CA E )v e r s i o n3 . 0 ,
with toxicity occurring within 3 months after the initia-
tion of RT classified as acute toxicity. Patients were con-
tacted and/or invited for follow-up 3-monthly during
the first year, 6-monthly thereafter.
Treatment evaluation
Response evaluation has been described extensively in
the previous pilot study in our institution [9]. Briefly, the
primary objective, CMR rate, was evaluated by comparing
the PET-CT at baseline with the PET-CT performed 3
months after initiation of RT, according to the PET
Response Criteria in Solid Tumors (PERCIST) version
1.0 [11]. A CMR in a patient was defined by a complete
resolution of
18FDG uptake within all irradiated lesion(s),
so that it is less than mean liver activity and indistin-
guishable from surrounding background blood-pool
levels, without new
18FDG-avid lesions in pattern typical
of CRC. For a partial metabolic response (PMR), a reduc-
tion in SUVmax for patients with one lesion or a reduc-
tion of the sum of the SUVmax data for patients with > 1
lesion of minimum 30% was required, without the
appearance of new
18FDG-avid lesions. Obvious progres-
sion of any lesion (> 30% increase in SUVmax)o rn e w
18FDG-avid lesions negate a partial response and indicate
progressive metabolic disease (PMD). Stable metabolic
disease (SMD) is defined as not CMR, PMR, or PMD.
During follow-up, the Response Evaluation Criteria in
Solid Tumors (RECIST) were used to evaluate response. A
local recurrence was defined as the re-growth of tumor
within or at the periphery of the irradiated volume. The
appearance of new lesions was considered as distant
recurrence.
Statistics
A Richard Simon two-stage optimal design was per-
formed to obtain the sample size. Aiming at an overall
acceptable and unacceptable CMR probability of 50%
and 30%, respectively, with an a and b value of 0.10, the
sample size for first and second stage were 7/22 and 17/
46 evaluated patients, respectively. Actuarial LC, PFS
and OS rates were estimated by Kaplan-Meier analysis,
Log-rank testing was used to evaluate the association
between patient-related factors and treatment outcome.
Laboratory tests were evaluated by t tests.
Results
Patient characteristics
Twenty-four inoperable oligometastatic CRC patients
with a total number of 53 metastases were enrolled
between March 2010 and July 2011. Patient characteris-
tics are given in Table 1. Seventeen patients (71%)
received previously ≥ 1 line of chemotherapy for meta-
static disease, of which 7 and 10 patients presenting
residual and progressive metabolic active oligometastatic
disease at time of inclusion, respectively. Seven patients
(29%) received no previous chemotherapy for treatment
of metastatic disease; 5 patients were medically unfit to
undergo systemic therapy and 2 patients refused
chemotherapy.
Seventeen patients (71%) received previous local ther-
apy for metastatic disease; radiotherapy (n = 7), RFA
(n = 6) and/or metastasectomy (n = 8). Twelve patients
(50%) presented with a GTV located in the vicinity of
hollow viscous organs (small/large bowel, stomach or
esophagus).
Table 1 Patient characteristics (n = 24)
Variable Distribution No. of Patients %
Sex Male 14 58
Female 10 42
Age (years) Median 67 years
Range 45 - 91 years
Karnofsky Performance status Median 90
Range 50 - 100
Previous chemotherapy 0 7 29
(number of lines) 1 3 13
21 0 4 2
32 8
42 8
Previous local therapy No 7 29
for metastases Yes 17 71
Number of metastases 1 10 42
25 2 2
34 1 6
44 1 6
51 4
Gross tumor volume (cc) Median 7 cc
Range 1 - 100 cc
Number of involved sites 1 17 71
24 1 7
33 1 2
Localization Liver 7 29
Lymph node 9 38
Lung 13 54
Peritoneum 2 8
Follow-up (months) Median 10 months
Range 3 - 21 months
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All patients finished their RT course without interrup-
tions of toxicity reasons. Grade 3 acute adverse events
were observed in 1 patient (4%), which displayed grade
3 dysphagia due to irradiation of an infracarinal lymph
node metastasis. No other grade ≥ 3 acute side effects
occurred. Two patients (8%) and 1 patient (4%) experi-
enced grade 2 dysphagia and diarrhea after irradiation of
mediastinal and pelvic lymph node metastases, respec-
tively. Of the 14 patients that were irradiated for lung
and/or mediastinal lymph node metastases, 5 patients
(36%) and 4 patients (29%) displayed grade 1 pneumoni-
tis (asymptomatic, radiographic findings only) and grade
2 pneumonitis (symptomatic, not interfering with activ-
ities of daily living), respectively. The recorded average
V20 of the lung for the 5 patients without pneumonitis
was 6.9% ± 4.1% compared to 15.7% ± 8.6% for patients
with grade ≥ 1 pneumonitis (n = 9) (p = 0.06). Average
functional liver volume (liver - GTV) for the patients
irradiated for liver metastases (n = 7) was 1412 cc ± 265
cc. No radiation-induced liver disease (RILD) was
observed in those 7 patients. With recorded average V22
and V30 of the liver of 27.0% ± 12.7% and 16.0% ± 7.5%,
respectively, no violation of the liver dose-volume con-
straints occurred. At a median follow up of 10 months
(range, 3 - 21 months), 1 patient (4%) that was irradiated
on 4 lymph node metastases in the coeliac and liver hilar
region developed grade 2 pyloric ulcera 7 months after
the end of RT. The dose to the nearby stomach and duo-
denum was limited to maximal 4 Gy/fraction in this
patient. Endoscopic biopsy in this patient suggested the
presence of gastric antral vascular ectasia. No grade 3
late adverse events occurred until now.
Response evaluation
Two out of 24 enrolled patients failed to receive a PET-CT
3 months after the initiation of RT, 1 because of poor gen-
eral condition and 1 being evaluated in another institution
after the end of treatment. Six patients (27.3%) achieved a
complete metabolic response (CMR), 6 patients (27.3%) a
partial metabolic response (PMR), resulting in an overall
metabolic response rate of 55%. The mean fractional
change in SUVmax at evaluation as compared to baseline
was -56.1% (range, 43.5% - 70.2%) and -40.2% (range,
33.3% - 45.1%) for complete and partial metabolic respon-
ders, respectively. Figure 1 illustrates a CMR in a patient
treated for lungmetastasis. Metabolic response rates are
listed in Table 2. Seven patients (32%) displayed progres-
sive metabolic disease (PMD), of which 6 patients at
distance and 1 patient both in- and outfield. Three
patients (13%) presented stable metabolic disease (SMD).
Regarding the 17 patients who received previously ≥ 1l i n e
of chemotherapy, a metabolic response was recorded in
86% (n = 5) of the patients with residual metabolic active
d i s e a s ea tt i m eo fi n c l u s i o n ,c o m p a r e dt oa4 0 %( n=4 )
metabolic response rate in the patients with progressive
metabolic active disease before RT. Lastly, 50% (n = 3) of
the evaluated patients who did not receive previous che-
motherapy for treatment of metastatic disease displayed a
metabolic response 3 months after initiation of RT. Moni-
toring of the tumor marker CEA at baseline showed a
mean value of 8.8 ± 8.7 ug/L for the whole patient group,
with elevated CEA (> 3 ug/L) recorded in 71% (n = 14) of
the patients. A significant decrease of the CEA level was
recorded in patients with a CMR or PMR (n = 12), with a
mean value of 7.7 ± 8.6 ug/L pretreatment compared to
4.6 ± 6.6 ug/L 3 months after initiation of RT (p = 0.01).
Metabolic non-responders (SMD or PMD, n = 10)
displayed a pretreatment CEA level of 10.5 ± 9.5 ug/L,
compared to a posttreatment value of 27.5 ± 41.6 ug/L
(p = 0.18).
Follow-up
With a median follow-up of 10 months (range, 3 - 21
months), 7 patients (29%) are in remission in all irradiated
areas without evidence of distant recurrence. Five patients
died, 4 because of progressive metastatic disease and 1
because of non-cancer related cerebral bleeding. Seventeen
patients (71%) developed progressive disease, of which 10
patients distant recurrence, 6 patients synchronous local
and distant progression, and 1 patient with isolated local
recurrence, the latter underwent wedge resection of a soli-
tary progressive lung metastasis. Among the other 16
patients with progressive disease, 5 patients received best
supportive care (BSC), 6 patients systemic therapy, 4
patients an additional course of RT (2 patients because of
distant relapse and 2 patients for local and distant relapse),
1 patient underwent metastasectomy of a new livermetas-
tasis. We report a 1-year actuarial LC, PFS and OS of 54%
(95% C.I. 23-78%), 14% (95% C.I. 3-35%) and 78% (95% C.
I. 52-91%), respectively. Log-rank testing found a statisti-
cally significant benefit of the post-treatment outcome in
terms of PFS for patients with a metabolic response (CMR
+ PMR) at 3 months after RT as compared with metabolic
non-responders (SMD + PMD) (p < 0.01). For the patients
who received previous chemotherapy (n = 17), log-rank
testing revealed that patients with residual disease pre-RT
exhibited a trend toward superior PFS (p = 0.05) com-
pared with patients presenting progressive disease at time
of inclusion, whereas LC and OS were not significantly dif-
ferent (p = 0.63 and p = 0.18, respectively) [Figure 2]. Of
the 7 patients which were in remission at a median follow-
up of 10 months, 5 had residual oligometastatic metabolic
active disease after previous chemotherapy at time of
inclusion. Factors such as number of metastatic lesions,
number of involved sites or number of previous lines of
chemotherapy were not correlated with post-treatment
outcome.
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Laboratory and clinical data recently supported the
hypothesis that oligometastatic disease is a distinct clini-
cal entity, where tumors early in the evolution of meta-
static progression produce metastases limited in number
and location [12-14]. The potential temporal evolution
with the intermediate stage of limited metastatic capa-
city, where oligometastatic tumors may not have
acquired the broad array of genetic changes to develop
widespread metastases, is strongly suggested by novel
insights into the metastatic evolution of pancreatic can-
cer [12,14]. Yachida and Campbell et al. discovered that
the clonal populations which give rise to distant metas-
tases were genetically evolved from the original non-
metastatic clone, with a required time period of at least
5 year before full acquisition of metastatic ability
[12,14]. The proposed hierarchal character of metastatic
p r o g r e s s i o ni nt i m ea n dn u m b e ri nt h o s el a n d m a r k
investigations emphasizes the need of aggressive treat-
ment of oligometastases, which may affect cure rates in
a selected proportion of metastasized patients [13].
Especially, the treatment of oligometastatic CRC
remains an attractive area of investigation as CRC
patients tend to develop metastases limited in number
and location. It is well accepted that complete resection
of CRC liver metastases provides a real chance for long-
term survival, with reported 5-year OS rates of 30-40%
Figure 1 Complete metabolic response displayed in a colorectal cancer patient with a solitary lung metastasis.( A) Pre-treatment
18 F-
fluorodeoxyglucose (FDG)-positron emission computed tomography (PET-CT) of a metastatic colorectal cancer patient with a solitary metabolic
active lungmetastasis. (B) Planning CT with superimposed radiation dose distribution. (C) Complete metabolic remission on PET-CT scan 3
months after initiation of radiotherapy. (D) PET-CT performed 6 months after completion of radiotherapy shows no evidence of progressive
disease, but note the occurrence of an asymptomatic radiation induced pneumonitis around the irradiated metastasis (white arrow).
Table 2 Metabolic response rate 3 months after start of
radiotherapy by
18 F-fluorodeoxyglucose (FDG)-positron
emission tomography (PET) (n = 22 patients)
No. of patients %
Complete metabolic response 6 27.3
Partial metabolic response 6 27.3
Stable metabolic disease 3 13.6
Progressive metabolic disease 7 31.8
No PET 2
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dures and preoperative multi-agent chemotherapy, lim-
itations imposed by localization, multifocal character,
size, or comorbidities still exclude the major part of
mCRC patients from undergoing metastasectomy
[17,18]. Recent evolutions in conformal RT and IGRT
have driven the development of SBRT, of which the
physical properties allow sparing of the surrounding
normal tissues with consequently fewer side effects to
be expected [7,10]. Next, it enables delivery of tumorici-
dal doses of radiation in a minimal number of fractions
to small target volumes. In the eradication of CRC liver-
and/or lungmetastases, minimal toxicity and sustained
LC rates of 53%-100% are reported with the use of
SBRT [8,19,20]. However, SBRT requires a careful selec-
tion of the metastases on the base of their localization
and dimension, as patients with metastases situated in
the proximity of hollow viscous organs such as small
bowel, esophagus or stomach could experience unaccep-
table normal tissue toxicity with the delivery of ablative
radiation doses by SBRT [21]. In order to suit a variety
of treatment sites, we explored in a previous study in
our institution the use of moderately hypofractionated
IMRT-IGRT (10 fractions of 4 Gy) by helical tomother-
apy in oligometastatic CRC [9]. Taking into account the
very limited toxicity (4% grade 3 toxicity) and the rela-
tively high local progression (22%) of irradiated metas-
tases without development of new metastases in this
trial, the aim was on higher response rates and LC. In
this report, we present the results of a prospective phase
II trial of helical tomotherapy delivering 50 Gy in daily
fractions of 5 Gy to inoperable oligometastatic CRC
patients. The primary objective was to evaluate the
C M Rr a t eb yc o m p a r i n g
18FDG-PET 3 months after
initiation of RT with
18FDG-PET at baseline. A sample
size for first stage of 7/22 was calculated based on a
Richard Simon two-stage optimal design aiming at an
overall acceptable and unacceptable CMR probability of
50% and 30%, respectively. After having evaluated 22
patients by
18FDG-PET, a CMR was documented in 6
patients. As 10 fractions of 5 Gy showed lower than
expected activity in first stage (6/22), the second stage
Figure 2 Local control (LC), progression-free survival (PFS) and overall survival (OS) rates among the whole patient group, previous
systemically treated patients displaying residual metabolic active oligometastatic disease at time of inclusion (n = 7) and patients
with progressive metabolic active disease before RT (n = 10). Log-rank testing was used to evaluate the association between response on
previous chemotherapy and treatment outcome, with p values reported.
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minated. Indeed, the overall metabolic response rate of
55% at 3 months and 1-year LC rate of 54% are similar
to the rates observed after 10 fractions of 4 Gy in our
previous study [9]. In comparison, Milano et al. reported
with 50 Gy in 10 fractions in oligometastatic patients a
2-year LC rate of 67% [22]. One should bear in mind
that LC rates of more than 95% with SBRT are reported
with biologically effective doses (BED) of > 100 Gy,
which can be only safely delivered in patients ideally
with maximal 3 metastases of less than 4 cm in dia-
meter and far from hollow viscous organs. Although not
superior to 10 fractions of 4 Gy, the delivery of 50 Gy
(BED of 75 Gy assuming an a/b of 10 for tumor
response, corresponding to a biologically equivalent
total dose in 2-Gy fractions (EQD2Gy) of 62.5 Gy) with
IMRT-IGRT by helical tomotherapy in a non-selected
patient population resulted in a promising overall
response rate of 55%, which is higher than the response
rates achieved with second- and third-line systemic
treatment regimens in mCRC, which are within the
range of 9-37% [3,23].
Of notice, we enrolled in our previous study mCRC
patients who already received previous systemic treatment
only in the case when they presented progressive disease
or cumulative toxicity limiting further continuation of sys-
temic treatment [9]. Actually, not only patients with pro-
gressive disease or cumulative toxicity limiting further
continuation of systemic treatment were enrolled in the
current study, but also mCRC patients with residual meta-
bolic active oligometastatic disease after effective previous
systemic treatment (n = 7). The use of helical tomotherapy
as consolidation appeared to be highly attractive in this
s u b g r o u p ,r e f l e c t e db ya8 6 %m e t a b o l i cr e s p o n s er a t ei n
those patients, and a trend toward increased PFS (p =
0.05) as compared to the patients with no response on
previous systemic treatment. At a median follow-up of
10 months, 71% of those patients (n = 5) are still in remis-
sion in all irradiated areas without evidence of distant pro-
gression, whereas 4 of the 10 patients presenting
progressive disease after previous chemotherapy at time of
inclusion already died because of progressive metastatic
disease. To our knowledge, these findings for the first time
indicate a potential role for the use of RT as consolidation
of previous systemically treated oligometastatic CRC. This
creates opportunities for future trials of SBRT that should
tailor inoperable oligometastases according to their pre-
vious response to systemic treatment, finally to resolve its
value in this patient population which is historically con-
sidered to be incurable when treated with chemotherapy
alone. Only in abstract form, Ruers et al. recently sug-
gested as first a potential benefit for combining systemic
and local treatment in mCRC by presenting the results of
a randomized phase II study which evaluated the benefit
of RFA combined with chemotherapy compared to che-
motherapy alone in 119 mCRC patients with unresectable
liver metastases [24]. Although a statistically significant
benefit in median PFS has been reported for the RFA +
chemotherapy arm (16.8 months versus 9.9 months for
patients receiving chemotherapy alone, p = 0.03), the fol-
low-up and study design (primary endpoint: 30-months
OS > 30%) do not allow a formal comparison between the
2 treatment arms in terms of OS [24]. Lastly, in concor-
dance with our previous experience, a metabolic response
(CMR or PMR) 3 months after initiation of RT was also
found to be predictive in terms of time to progression (p <
0.01). Hence,
18FDG-PET should be offered complemen-
tary to anatomical imaging for all oligometastatic CRC
patients undergoing a RT course.
The delivery of 50 Gy in 10 fractions by the combination
of dose sculpting by IMRT with image-guidance techni-
ques by the Tomotherapy Hi-Art II System appeared to be
a safe regimen, with grade 3 acute and late toxicity
recorded in only 1 patient. The lowering of the maximal
dose to 4 Gy/fraction on the stomach and duodenum did
not prevent the occurrence of grade 2 pyloric ulcera in the
patient treated because of 4 perihilar lymph node metas-
tases. Taking into account the radiosensitive nature of the
stomach and duodenum, patients with metastases located
in the proximity of those organs should be excluded from
high-dose SBRT. The limited toxicity in the present study
in a patient population with critically located lesions sup-
ports the further use of a moderately hypofractionated RT
regimen, such as 10 × 5 Gy.
Finally, from a technical point of view, the IGRT solu-
tion in the Tomotherapy Hi-Art II system allows only
pre-treatment management of tumor motion by volu-
metric imaging (MV-CT) and thus requires the applica-
tion of CTV to PTV margins in the order of 1 cm to
account for intrafraction tumor motion, for example in
the lung and liver. Theoretically, real-time tracking of
the metastases during treatment should allow a strong
reduction of the CTV to PTV margin, and thus less
healthy tissues need to be irradiated. This is especially
attractive in performing dose escalation in critically
located lesions, as classical CTV to PTV margins result
in significant overlap between PTV and organs at risk,
the latter limiting delivery of cytotoxic doses with regard
to normal tissue toxicity. The VERO system is a novel
platform for image-guided SBRT designed to anticipate
tumor motion during treatment by real-time tracking of
the target [25]. Its dynamic capabilities have been
explored currently in our department and a clinical trial
investigating its value in the eradication of inoperable
oligometastases will be initiated. In the context of dose
escalation, one should also mention the potential of
Engels et al. Radiation Oncology 2012, 7:34
http://www.ro-journal.com/content/7/1/34
Page 7 of 9particle therapy, being proton therapy the example, in
minimizing the irradiated volume of the surrounding
healthy tissues compared to 3D conformal RT and
IMRT [26].
Conclusions
In conclusion, 10 fractions of 5 Gy resulted in a promis-
ing metabolic response rate of 55% and limited toxicity.
Helical tomotherapy may further play a substantial role
in the multidisciplinary treatment of inoperable oligo-
metastatic CRC, especially as consolidation in patients
with residual oligometastatic disease after being treated
systemically.
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